In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin. (Source: CancerNetwork)
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tpE7Ok
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Assessment of water quality status of a river with respect to its discharge has become prerequisite to sustainable river basin man...
-
Abstract Objectives Patients undergoing osteoporosis treatment benefit greatly from early detection. We previously developed a computer-...
-
Publication date: Available online 20 March 2018 Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology Author(s): Tobia...
-
Cerebral Microbleeds: Imaging and Clinical Significance. Radiology. 2018 Apr;287(1):11-28 Authors: Haller S, Vernooij MW, Kuij...
-
by Alison M. Hixon, Guixia Yu, J. Smith Leser, Shigeo Yagi, Penny Clarke, Charles Y. Chiu, Kenneth L. Tyler In 2014, the United States exp...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου